Introduction
Since its introduction into clinical practice in 1964, pulse oximetry has grown to the extent where today it is used across all medical specialties. It provides the fundamental parameter of oxygen saturation of hemoglobin non-invasively, continuously and in real time. Although it now is used as the '5th Vital Sign,' potential interferers must be continually scrutinized to ensure its validity and accuracy. As a case in point, we report potential interference with pulse oximetry saturation (SpO 2 ) values in an infant with bronze baby syndrome (BBS), resulting from Rhesus (Rh) hemolytic disease treated with phototherapy. Inconsistencies between pulse oximetry and arterial oxygen partial pressure (PaO 2 ) measurements called into question the validity of the SpO 2 readings in this disease setting.
Case
The neonate was male, weighed 2370 g and was delivered spontaneously at 33 weeks gestation to a gravida 3, para 3, woman of Peruvian descent. Her earlier children experienced no neonatal difficulties and were alive and well. The mother's blood group was O, Rh negative and her serum contained anti-D antibodies. No anti-D was administered during any of her pregnancies. The infant's blood group was O, Rh positive and he had a strongly positive direct Coombs' test.
The infant was delivered pale and in respiratory distress with Apgar scores of 9 and 10 at 1 and 5 min, respectively. He was admitted to the neonatal unit, where he exhibited signs consistent with cardiac failure. Initial packed cell volume was 0.2 and the cord bilirubin of 153 mmol l À1 (8.9 mg dl À1 ) rose to 250 mmol l À1 (14.6 mg dl À1 ) in the first 4 h. An echocardiogram showed a structurally normal heart and cardiac failure that resolved with correction of his anemia.
The infant was treated with an initial blood transfusion and triple phototherapy, but subsequently required a double volume exchange transfusion every day for the first 3 days of life to control the rising levels of bilirubin (maximum bilirubin was 326 mmol l À1 (19 mg dl À1 )). After the first exchange, the packed cell volume was 0.5 and remained above this level until discharge. On day 2 the conjugated fraction of bilirubin was noted to be rising and by day 6 it had reached its apogee at 214 mmol l À1 (12.5 mg dl À1 ). Bronze skin color and dark urine were noted clinically on day 4, but had completely faded by discharge on day 22. The infant produced normal stools throughout his hospital course. Liver function tests showed a normal alanine aminotransferase and aspartate aminotransferase, but a moderate elevation in g-glutamyl transpeptidase, which peaked at 135 iu l À1 on day 6 and subsequently normalized. Phototherapy was stopped on day 5 for a period of 9 h while the infant was out with mother, after which it was restarted and continued until day 7.
By day 2 the infant's respiratory distress had resolved, but he remained in 30% oxygen to maintain his SpO 2 >92%. His oxygen requirement on the basis of his SpO 2 (measured both by Philips M1020A, Philips Medical Systems UK and Ireland, Surrey, UK and Masimo SET RA5, Masimo, UK, Basingstoke, Hants, UK) gradually increased and reached 60% by day 5. Changes in inspired oxygen, however, did not lead to concomitant changes in SpO 2 and an arterial blood gas done on day 5 with SpO 2 readings consistently at 85% showed a PaO 2 of 27.2 kPa (204 mmHg). SpO 2 monitoring was then stopped for a period that corresponded with a 9-h phototherapy break and when recommenced SpO 2 readings in air of 100% were obtained. Over the next 7 h, under phototherapy, the SpO 2 settled to 90% with no response to increases in inspired oxygen. Continuous SpO 2 readings were stopped, but intermittent readings showed a normalization of SpO 2 by day 8 to >92%.
The infant spent the remaining days of his admission by establishing feeds and was discharged on day 22 weighing 2410 g.
Discussion
Developed in the 1970s, light-weight portable pulse oximetry exploits the difference in the spectral absorbance of deoxygenated and oxygenated hemoglobin. Two wavelengths of light, infrared (940 nm) and red (660 nm) are shone through a peripheral tissue, usually the hand or foot in neonates, and sensors determine the quantity of light transmitted, calculating absorbed light as the difference between incident light and transmitted light. Calculations using the plethymographic waveform eliminate spectral absorbance of the tissues, thereby isolating the spectral properties unique to the arterial pulsation of blood.
Both the Masimo SET RA5 (Masimo, UK) and Philips M1020A (Philips Medical Systems, UK and Ireland) used in our patient are pulse oximeters that use dual frequency absorbances to calculate SpO 2 . The Masimo SET has been independently validated. 1 A compound that can potentially interfere with SpO 2 measurements must be present in the arterial blood and have spectral absorbances overlapping the red or the infrared frequencies.
2,3
Ralston AC et al. reported that bilirubin introduces no significant errors in SpO 2 measurement. This can been explained by bilirubin's spectral absorbance, which does not extend to wavelengths of 500 nm. 4 In our infant, when SpO 2 readings of 85% were obtained concomitant with a PaO 2 of 27.2 kPa and no respiratory distress, we concluded that SpO 2 values might be underestimating the true SaO 2 and that this was because of an interfering compound. We searched the literature to find precedence for this observation in infants with BBS.
Bronze baby syndrome Bronze baby syndrome, which is associated with phototherapy, seems to be caused by an abnormal accumulation of porphyrins, namely copper (II) porphyrins, as a consequence of cholestasis. This accretion of porphyrins may be a result of the erythroid and hepatic hemopoietic hyperactivity, as seen in our case of Rh disease. [5] [6] [7] Copper (II) porphyrins found in the plasma and tissues of infants with BBS, in the presence of bilirubin, are susceptible to phototherapy (blue light)-induced photodestruction, resulting in brown photoproducts. 5, 6, 8 Such brown pigments, in which structure has yet to be delineated, are thought to be responsible for the bronze discoloration seen in BBS. They have spectral characteristics that resemble those isolated in the sera of infants with BBS, which show a generalized absorption in the near ultraviolet and red spectral regions. 8 Regardless of its precise nature, the brown pigment present in the plasma (and therefore the plethymographic waveform) of infants with BBS possesses the correct spectral characteristics (broad band of red absorbance) to potentially interfere with SpO 2 readings.
In our patient, SpO 2 readings fell concomitant with the peak levels of direct bilirubin, but rose after a period off phototherapy, implicating bilirubin or at least a proxy of bilirubin and the continuing use of phototherapy in generating the SpO 2 interference. These observations would be consistent with a hypothesis involving the production of brown pigments as a result of porphyrin destruction, as such destruction has been shown to require both the presence of bilirubin and phototherapy. The direction of interference suggested is that of underestimation of SpO 2 , similar to the pattern of interference generated by methemoglobin, which was not detected in our patient.
This case has highlighted the need to interpret SpO 2 readings in infants with BBS with circumspection, but further investigations need to be done to validate this observation and clarify the nature of the brown pigments that are produced by phototherapy during hyperbilirubinemia.
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